Tracking Blood Sugar With a Sensor in Diabetes and Stomach Paralysis
Tests a glucose sensor in adults with diabetes, with and without gastroparesis.
Plain-language title generated from the registry record
Registry title: Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
Key facts
- Where
- Cleveland, United StatesSee the site
Where in United States
- Cleveland Clinic FoundationCleveland, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samita Garg
- Trial code
- NCT06046833
- Record updated
- 3 August 2026
- Original description
A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.Read full original descriptionShow less
Glucose Metrics Using Freestyle Libre 3 Real-Time Continuous Glucose Monitor (rtCGM) in Patients With Gastroparesis in Type 1 or Type 2 Diabetes: Investigator Initiated Pilot Study
A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.
Inclusion: Over the age of 18 years; Hemoglobin A1c ≤11% within the last 6 months; Patients with diagnosis of type 1 Diabetes or type 2 Diabetes for at least one year; Normal thyroid-stimulating hormone (TSH) within the last year; No episodes of diabetic ketoacidosis (DKA), Hyperosmolar Hyperglycemic Status (HHS), or hypoglycemia in the past 2 weeks requiring ER visit or hospitalization; Symptoms of gastroparesis have been present for at least the past 3 months, in patients with gastroparesis; In patients with gastroparesis, documented delayed gastric emptying on scintigraphy and/or wireless motility capsule (Smart Pill) as defined by greater than 10% retention at 4 hours or greater than 4-hour gastric transit time (GTT) in the past five years; Patients using a Smartphone (iPhone or Android) compatible with LibreView App.
Exclusion: Post-transplant patients; Patients on opiates or glucagon-like peptide-1 (GLP-1) agonists (Ozempic, Wegovy, Mounjaro, Trulicity). If previously taking these medications, patients can be enrolled after 2 weeks of the last dose; Patient on recreational or illicit drugs (i.e., marijuana, opiates, cocaine, etc.); Patients on motility medications such as Reglan (Metoclopramide), Motegrity (Prucalopride), Cisapride, Domperidone, Erythromycin. If previously taking any of these medications, patients can be enrolled after 1 week of the last dose; Patient previously participated in the study; Advanced and significant cardiovascular disease or unstable angina; History of gastric surgery; Patients with symptoms secondary to celiac disease (e.g. diarrhea, nausea, vomiting, abdominal pain) at the time of the enrollment; Hemoglobin A1c of >11% at enrollment; Advanced chronic kidney disease (serum creatinine of >2 mg/dL or estimated glomerular filtration rate (eGFR) <30mL/min/1.73m² using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula); Advanced liver disease that may affect glucose profiles; Patients on steroids or immunomodulators or chemoradiation that might affect glucose profiles; Pregnancy or women of reproductive age group not taking adequate precautions for pregnancy for 28 days; Clinically significant abnormalities on upper GI endoscopy; Presence of imaging evidence of gastric or intestinal obstruction.